|
| Friday, February 14, 2025 |
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
| In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
| Friday, January 24, 2025 |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| more info >> |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
| Thursday, January 9, 2025 |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
| Monday, December 9, 2024 |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
| China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
| Monday, December 2, 2024 |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
|
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利 |
| 康哲藥業控股有限公司（以下簡稱「康哲藥業」）欣然宣佈，於2024年12月2日，通過其全資附屬公司與杭州新元素藥業有限公司（以下稱「新元素藥業」，曾用名「江蘇新元素醫藥科技有限公司」）就治療痛風及高尿酸血症的1類新藥ABP-671（「產品」）簽訂獨家商業化協議（「協議」）。 more info >> |
|
|
|
|
